Prometheus Laboratories

Prometheus empowers you to diagnose, treat and help get your IBD patients into remission faster with precision-guided care. Our newest innovation, PredictrPK®, offers dose optimization strategies for infliximab, adalimumab, and their respected biosimilars in support of sustained clinical remission, drug persistence, and improved outcomes. PredictrPK measures current drug and anti-drug antibody levels AND predicts optimal, individualized dosing by analyzing your patient’s unique pharmacokinetics. 

Other tests in our proprietary portfolio include:

Anser®: A drug-tolerant therapeutic drug monitoring test that uniquely measures serum drug levels and anti-drug antibodies for IFX, IFX biosimilars, adalimumab, ADA biosimilars, vedolizumab, or ustekinumab. 

Monitr®: The first serum monitoring test to provide a non-invasive measure of endoscopic healing in adult Crohn’s Disease patients.